Gapping up
In reaction to earnings/guidance:
- EXPR +26.3%, NARI +11.6%, OM +11.5%, UNFI +11.4%, LPRO +8.9%, CLNE +8%, GSKY +7.2%, ABM +6.1%, AEGN +3.3%, MDB +2.3%
Other news:
- MNOV +95.2% (announced partnership with BARDA to develop MN-166 as medical countermeasure against chlorine gas-induced lung injury)
- XELA +22.6% (after closing higher by +180%)
- AFMD +12.4% (announces continuation of REDIRECT, a registration-directed study of AFM13 in PTCL, after positive preplanned interim futility analysis)
- BLDP +9.3% (to provide fuel cell modules for Canadian Pacific's [CP] Hydrogen Locomotive Program)
- BLUE +9.2% (provides updated findings from reported case of AML in LentiGlobin for sickle cell disease gene therapy program)
- VBIV +7.9% (initiated enrollment in Phase 1/2 study of prophylactic COVID-19 vaccine candidate VBI-2902; VBI Vaccines and CEPI to collaborate on advancing vaccine candidates against COVID-19 variants)
- CLNE +7.8% (Clean Energy Fuels will work with BP Products North America to develop, own and operate new renewable natural gas facilities at dairies and other agriculture facilities)
- HTOO +6.5% (announced MoU with Magnesitas De Rubian for green hydrogen solutions for mining sector)
- ETM +3.8% (announced the acquisition of Podcorn)
- IAC +3.3% (reported February metrics)
- ALKS +2.8% (receives FDA orphan designation for treatment of mucosal melanoma)
- PENN +2.7% (approved to launch Barstool Sportsbook mobile app in Illinois)
- ANGI +2.3% (reported February metrics)
- GLP +2.2% (lightly traded)
- TOL +2.2% (raised dividend)
- COHR +2.2% (Coherent enters revised merger agreement with Lumentum Holdings (LITE))
Analyst comments:
- RUN +6.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- MTLS +4.2% (upgraded to Buy from Neutral at Bryan Garnier)
- SSYS +3.9% (upgraded to Neutral from Underweight at JP Morgan)
- TS +2.6% (upgraded to Equal Weight from Underweight at Barclays)
- BSY +1.6% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- ECOL +1% (upgraded to Outperform from Perform at Oppenheimer's Kansas City Capital)